In her current role, Suzanne focuses on commercial strategy and growth for Tempus developing and executing partnerships with organizations to improve healthcare value and outcomes by leveraging molecular and clinical data. Value creation for commercial payers, benefit managers and group purchasing organizations is where she focuses. Dr. Belinson is especially interested in applications of data to power solutions for the transition to and management of value based care. Prior to Tempus, Dr. Belinson served as Executive Director, Clinical Markets, at the Blue Cross Blue Shield Association where she led the sales and market development as well as day to day operations of Evidence Street. Dr. Belinson received her bachelor’s degree from Cleveland State University, a Masters in Public Health from the University of Pittsburgh, and a PhD in Epidemiology from the University of North Carolina at Chapel Hill.
Cancer genomic profiling can identify germline and medically actionable mutation(s) in cancer predisposition genes. This can present a complex problem for diagnostics labs because of broader implications regarding the patient’s overall health risk, risk of future cancers, and implications for the patient’s family. This panel discussion will focus on how diagnostics labs are addressing this complexity.